Showing 2231-2240 of 5643 results for "".
- FDA Approves Xdemvy, First Treatment for Demodex Blepharitishttps://modernod.com/news/fda-approves-xdemvy-first-treatment-for-demodex-blepharitis/2481743/The FDA has approved Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution 0.25%) for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause
- Dean Burns Named President and CEO of Ocumeticshttps://modernod.com/news/dean-burns-named-president-and-ceo-of-ocumetics/2481722/Ocumetics Technology has appointed ophthalmic executive Dean Burns as President and CEO. Mr. Burns, whoj will also join the Ocumetics board of directors, was previously a consultant for Ocumetics, assisting with regulatory and marketing endeavours. Mr. Burns replaces 
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congresshttps://modernod.com/news/nicox-presents-ncx-470-phase-3-mont-blanc-adaptive-design-data-and-additional-subset-analysis-at-the-world-glaucoma-congress/2481705/Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data generated in the Mont Blanc phase 3 trial on NCX 470 has provided us with the opportunity to look in detail at patient subgroups to further
- The International Agency for the Prevention of Blindness (IAPB) Welcomes Over 300 International Delegates to Singaporehttps://modernod.com/news/the-international-agency-for-the-prevention-of-blindness-iapb-welcomes-over-300-international-delegates-to-singapore/2481690/The International Agency for the Prevention of Blindness (IAPB) has welcomed more than 300 delegates to Singapore for its "2030 IN SIGHT LIVE" event. Hosted in partnership with the Singapore Eye Research Institute (SERI), the event gathers experts and thought leaders from eye
- FDA Clearance Expands the Label of Eyenuk's EyeArt AI System for the Detection of DRhttps://modernod.com/news/fda-clearance-expands-the-label-of-eyenuks-eyeart-ai-system-for-the-detection-of-dr/2481685/Eyenuk has received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras. The regulatory clearance of t
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste
- Study: Lab-Grown ‘Mini-Corneas’ Mimic Developing Human Corneashttps://modernod.com/news/study-lab-grown-mini-corneas-mimic-developing-human-corneas/2481678/Researchers at NYU Langone Health say three-dimensional, lab-grown “mini-corneas” resemble the developing human cornea, potentially making them a new tool for the study of corneal diseases. P
- Beacon Therapeutics Launches with Goal of Developing Gene Therapies for Retinal Diseaseshttps://modernod.com/news/beacon-therapeutics-launches-with-goal-of-developing-gene-therapies-for-retinal-diseases/2481673/Beacon Therapeutics has launched and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including OSE, has provided £96 million ($120 million) to fund the acqu